EGFR Antikörper (Extracellular Domain) (FITC)

Produktnummer ABIN181808

Der Ratte Monoklonal Anti-EGFR-Antikörper wurde für FACS validiert. Er ist geeignet, EGFR in Proben von Human zu detektieren.

Kurzübersicht für EGFR Antikörper (Extracellular Domain) (FITC) (ABIN181808)

Target: EGFR (Epidermal Growth Factor Receptor (EGFR))

Reaktivität: Human

Wirt: Ratte

Klonalität: Monoklonal

Konjugat: Dieser EGFR Antikörper ist konjugiert mit FITC

Applikation: Flow Cytometry (FACS)

Klon: ICR10

Produktdetails anti-EGFR Antikörper (FITC)

Bindungsspezifität: Extracellular Domain

Spezifität: This antibody recognises the Epidermal Growth Factor Receptor (EGF-R), which is over expressed in a high proportion of breast cancer cells and in a range of other carcinomas. High level expression of EGFR is often associated with advanced disease and poor prognosis. The antibody binds to epitope B from EGFR (1,2).Aff. Const.:6.7 x 10e-9 M

Aufreinigung: Ion Exchange Chromatography.

Immunogen: Extracellular domain of human EGF-receptor from head and neck carcinoma

Isotyp: IgG2a

Anwendungsinformationen

Applikationshinweise: Flow Cytometry: Use 10 μL of 1/10 diluted antibody to label 10^6 cells in 100 μL.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.1 mg/mL

Buffer: PBS, pH 7.4 containing 0.09 % Sodium Azide as preservative and 1 % BSA as stabilizer.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing. Dilute only prior to immediate use

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Details zu EGFR

Target: EGFR (Epidermal Growth Factor Receptor (EGFR))

Andere Bezeichnung: EGFR / ERBB1

Hintergrund: EGF Receptor (EGFR) and erbB2, erbB3, and ErbB4 are members of subclass I of receptor tyrosine kinases. EGFR/erbB receptors are activated upon binding of EGF and EGF-related growth factors such as TGF alpha, beta-cellulin, Hb-EGF, HRG, or NRG. Binding of these ligands leads to receptor homo- and heterodimerization followed by autophosphorylation and activation of downstream signal transduction pathways (MAPK, PI3K/PKB, and STAT). In addition, EGFR becomes fully activated after phosphorylation of Y845 by src family kinases. Phosphorylation of Y1045 leads to association with cbl and subsequent receptor degradation. Phosphorylation of S1047 by CamKinase II leads to attenuation of kinase activity, phosphorylation of T654 (by PKC) and T669 (by MAPK, p38) interferes with receptor endocytosis/recycling.Synonyms: EGF Receptor, Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, c-ErbB-1, erbB-1

Gen-ID: 1956

NCBI Accession: NP_005219

UniProt: P00533

Pathways: NF-kappaB Signalweg, RTK Signalweg, Fc-epsilon Rezeptor Signalübertragung, EGFR Signaling Pathway, Neurotrophin Signalübertragung, Stem Cell Maintenance, Hepatitis C, Positive Regulation of Response to DNA Damage Stimulus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation, S100 Proteine